血清白细胞介素 6 (IL -6) 作为埃及 CLL 患者的预后指标

E. A. Hassan, E. Abdelhady, H. Abdelsamee, Mohamed Tarif Hamza sallam, M. El-Razzaz
{"title":"血清白细胞介素 6 (IL -6) 作为埃及 CLL 患者的预后指标","authors":"E. A. Hassan, E. Abdelhady, H. Abdelsamee, Mohamed Tarif Hamza sallam, M. El-Razzaz","doi":"10.18502/ijhoscr.v18i2.15369","DOIUrl":null,"url":null,"abstract":"Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Currently, several biomarkers are being used as CLL prognosticators, including elevated protein levels, elevated RNA levels, gene mutations, and epigenetic changes. \nMaterials and Methods: This study is a prospective study conducted on 55 patients newly diagnosed with CLL, serum IL-6 level was measured initially and after a 6-month treatment course. Correlation with the course of the disease and the known CLL prognostic parameters was done initially and after 6 months. \nResults: The initial serum IL-6 level in the patient group (pre-treatment) ranges from 36-91 pg/mL (median 57), and in the patient group (post-treatment) ranges from 1-32 pg/mL (median 2). Serum IL-6 level was positively correlated with WBC count, β2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes), and Binet and Rai staging systems. \nConclusion: Serum IL-6 is a useful poor prognostic marker in newly diagnosed CLL patients; its prognostic value goes with the other known prognostic markers such as the BM lymphocyte count, ESR, and LDH.","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"103 27","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum Interleukin 6 (IL -6) as Prognostic Marker in Egyptian CLL patients\",\"authors\":\"E. A. Hassan, E. Abdelhady, H. Abdelsamee, Mohamed Tarif Hamza sallam, M. El-Razzaz\",\"doi\":\"10.18502/ijhoscr.v18i2.15369\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Currently, several biomarkers are being used as CLL prognosticators, including elevated protein levels, elevated RNA levels, gene mutations, and epigenetic changes. \\nMaterials and Methods: This study is a prospective study conducted on 55 patients newly diagnosed with CLL, serum IL-6 level was measured initially and after a 6-month treatment course. Correlation with the course of the disease and the known CLL prognostic parameters was done initially and after 6 months. \\nResults: The initial serum IL-6 level in the patient group (pre-treatment) ranges from 36-91 pg/mL (median 57), and in the patient group (post-treatment) ranges from 1-32 pg/mL (median 2). Serum IL-6 level was positively correlated with WBC count, β2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes), and Binet and Rai staging systems. \\nConclusion: Serum IL-6 is a useful poor prognostic marker in newly diagnosed CLL patients; its prognostic value goes with the other known prognostic markers such as the BM lymphocyte count, ESR, and LDH.\",\"PeriodicalId\":94048,\"journal\":{\"name\":\"International journal of hematology-oncology and stem cell research\",\"volume\":\"103 27\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of hematology-oncology and stem cell research\",\"FirstCategoryId\":\"0\",\"ListUrlMain\":\"https://doi.org/10.18502/ijhoscr.v18i2.15369\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of hematology-oncology and stem cell research","FirstCategoryId":"0","ListUrlMain":"https://doi.org/10.18502/ijhoscr.v18i2.15369","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:慢性淋巴细胞白血病(CLL慢性淋巴细胞白血病(CLL)是成人中最常见的白血病。目前,有几种生物标志物被用作 CLL 的预后指标,包括蛋白质水平升高、RNA 水平升高、基因突变和表观遗传学变化。材料和方法:本研究是一项前瞻性研究,对 55 例新诊断为 CLL 的患者进行了血清 IL-6 水平测定,测定的对象包括最初和 6 个月疗程后的患者。最初和 6 个月后的血清 IL-6 水平与病程和已知的 CLL 预后参数之间存在相关性。结果显示患者组(治疗前)的初始血清IL-6水平为36-91皮克/毫升(中位数为57),患者组(治疗后)的初始血清IL-6水平为1-32皮克/毫升(中位数为2)。血清 IL-6 水平与白细胞计数、β2 微球蛋白、LDH、血沉、B 症状、尿酸、骨髓穿刺液(淋巴细胞百分比)以及 Binet 和 Rai 分期系统呈正相关。结论血清IL-6是新诊断的CLL患者预后不良的有用标记物;其预后价值与其他已知的预后标记物(如BM淋巴细胞计数、血沉和LDH)相同。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Serum Interleukin 6 (IL -6) as Prognostic Marker in Egyptian CLL patients
Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. Currently, several biomarkers are being used as CLL prognosticators, including elevated protein levels, elevated RNA levels, gene mutations, and epigenetic changes. Materials and Methods: This study is a prospective study conducted on 55 patients newly diagnosed with CLL, serum IL-6 level was measured initially and after a 6-month treatment course. Correlation with the course of the disease and the known CLL prognostic parameters was done initially and after 6 months. Results: The initial serum IL-6 level in the patient group (pre-treatment) ranges from 36-91 pg/mL (median 57), and in the patient group (post-treatment) ranges from 1-32 pg/mL (median 2). Serum IL-6 level was positively correlated with WBC count, β2 microglobulin, LDH, ESR, B symptoms, Uric Acid, BM Aspirate (% of lymphocytes), and Binet and Rai staging systems. Conclusion: Serum IL-6 is a useful poor prognostic marker in newly diagnosed CLL patients; its prognostic value goes with the other known prognostic markers such as the BM lymphocyte count, ESR, and LDH.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Response-Based Approach for Pediatric Hodgkin Lymphoma in Nations with Restricted Resources Relationship between Breast Cancer and Cardiac Myxoma Cyclophosphamide- Antifungals Interactions in Patients Undergoing Hematopoietic Stem Cell Transplantation: What Should We Know About it? Aplastic Anemia Following COVID-19 Vaccination: A Systematic Review of Case Reports and Case Series Unleashing the Impact of Exosomes Derived from Human Placental Mesenchymal Stem Cells (hPMSCs) on U-266 Myeloma Cell Line
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1